PLX PROTALIX BIOTHERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PROTALIX BIOTHERAPEUTICS INC reported revenue of $19.9M (up 27.1% from a year earlier), net income of $3.78M and diluted EPS of $0.05; over the last four quarters revenue was $80.6M and net income $18.9M; for the fiscal year ended December 2025 revenue was $52.7M, down 1.2% on the year before.
PLX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $52.7M, gross profit n/a, operating income −$5.50M, net income −$6.60M (margin -12.5%), EPS −$0.08
- Fiscal year ended Dec 2024: revenue $53.4M, gross profit n/a, operating income $3.92M, net income $2.93M (margin 5.5%), EPS $0.04
- Fiscal year ended Dec 2023: revenue $65.5M, gross profit n/a, operating income $10.5M, net income $8.31M (margin 12.7%), EPS $0.09
- Fiscal year ended Dec 2022: revenue $47.6M, gross profit n/a, operating income −$13.0M, net income −$14.9M (margin -31.3%), EPS −$0.31
- Fiscal year ended Dec 2021: revenue $38.4M, gross profit n/a, operating income −$20.5M, net income −$27.6M (margin -71.9%), EPS −$0.62
PLX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $19.9M (up 27.1% year over year), net income $3.78M, EPS $0.05
- Quarter ended Mar 31, 2026: revenue $33.8M (up 233.7% year over year), net income $18.3M, EPS $0.22
- Quarter ended Dec 31, 2025 (from the annual report): revenue $9.12M (down 49.9% year over year), net income −$5.50M, EPS −$0.06
- Quarter ended Sep 30, 2025: revenue $17.9M (down 0.6% year over year), net income $2.36M, EPS $0.03
- Quarter ended Jun 30, 2025: revenue $15.7M (up 16.2% year over year), net income $164K, EPS $0.00
- Quarter ended Mar 31, 2025: revenue $10.1M (up 169.8% year over year), net income −$3.62M, EPS −$0.05
- Quarter ended Dec 31, 2024 (from the annual report): revenue $18.2M (up 73.7% year over year), net income $6.49M, EPS $0.10
- Quarter ended Sep 30, 2024: revenue $18.0M (up 73.6% year over year), net income $3.24M, EPS $0.03
- Quarter ended Jun 30, 2024: revenue $13.5M (down 61.6% year over year), net income −$2.20M, EPS −$0.03
- Quarter ended Mar 31, 2024: revenue $3.75M (down 60.9% year over year), net income −$4.60M, EPS −$0.06
- Quarter ended Dec 31, 2023 (from the annual report): revenue $10.5M (up 21.7% year over year), net income −$6.04M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue $10.3M (down 27.1% year over year), net income −$1.85M, EPS −$0.04
- Quarter ended Jun 30, 2023: revenue $35.1M (up 300.7% year over year), net income $19.3M, EPS $0.21
- Quarter ended Mar 31, 2023: revenue $9.59M (down 40.4% year over year), net income −$3.13M, EPS −$0.05
- Quarter ended Dec 31, 2022 (from the annual report): revenue $8.62M (up 0.8% year over year), net income −$3.74M, EPS −$0.08
- Quarter ended Sep 30, 2022: revenue $14.2M (up 17.7% year over year), net income −$3.57M, EPS −$0.07
- Quarter ended Jun 30, 2022: revenue $8.75M (up 36.2% year over year), net income −$5.33M, EPS −$0.11
- Quarter ended Mar 31, 2022: revenue $16.1M (up 42.1% year over year), net income −$2.29M, EPS −$0.05
- Quarter ended Dec 31, 2021 (from the annual report): revenue $8.55M, net income −$6.67M, EPS −$0.14
- Quarter ended Sep 30, 2021: revenue $12.1M, net income −$4.20M, EPS −$0.09
PLX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $8.67M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.32M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$25.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$10.3M, share buybacks n/a
PLX balance sheet
- Jun 30, 2026: cash $27.4M, total assets $110M, total liabilities $38.9M, shareholders' equity $71.4M
- Mar 31, 2026: cash $41.0M, total assets $102M, total liabilities $35.1M, shareholders' equity $67.2M
- Dec 31, 2025: cash $14.7M, total assets $82.3M, total liabilities $34.1M, shareholders' equity $48.2M
- Sep 30, 2025: cash $13.6M, total assets $82.3M, total liabilities $29.4M, shareholders' equity $52.9M
- Jun 30, 2025: cash $17.9M, total assets $78.5M, total liabilities $28.6M, shareholders' equity $49.9M
- Mar 31, 2025: cash $19.5M, total assets $73.9M, total liabilities $28.7M, shareholders' equity $45.2M
- Dec 31, 2024: cash $19.8M, total assets $73.4M, total liabilities $30.2M, shareholders' equity $43.2M
- Sep 30, 2024: cash $27.4M, total assets $61.6M, total liabilities $29.1M, shareholders' equity $32.4M
What is PLX's revenue?
PROTALIX BIOTHERAPEUTICS INC reported $80.6M of revenue over its last four quarters, through June 30, 2026.
Is PLX profitable?
Yes. PROTALIX BIOTHERAPEUTICS INC earned $18.9M over the last four quarters.
What is PLX's EPS?
Diluted earnings per share over the last four quarters were $0.24; $0.05 in the latest quarter.